Phase 2Recruiting
Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment (MOMENTUM-1)
MOMENTUM-1: A Multicenter, Randomized, Open-Label, Phase II Study of [177LU]LU-DOTATATE in Adults With Progressive Intracranial Grade 1-3 Meningioma
- Sponsor
- RTOG Foundation, Inc. (Academic or other)
- Enrolment
- 130 planned
- Conditions
- Intracranial Meningioma
- Interventions
- [177Lu]Lu-DOTATATE; Standard of Care treatments
- Ages
- adults, older adults
- Registry
- NCT06955169
From the registry
This is an open-label, multicenter, randomized, phase 2 clinical study to evaluate the efficacy of \[177Lu\]Lu-DOTATATE in patients with progressive grade 1-3 intracranial meningioma.
Primary outcomes
- Progression Free Survival (PFS)